In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors Lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: A comparison with l-deprenyl
- 1 June 1995
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 50 (1) , 97-102
- https://doi.org/10.1016/0006-2952(95)00022-r
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Symptomatic Anti-Parkinsonian Effects of Monoamine Oxidase-B Inhibition: Comparison of Selegiline and LazabemideClinical Neuropharmacology, 1993
- A controlled trial of lazabemide (RO19–6327) in untreated Parkinson's diseaseAnnals of Neurology, 1993
- The Pharmacological Profile of (–)Deprenyl (Selegiline) and its Relevance for Humans: A Personal ViewBasic & Clinical Pharmacology & Toxicology, 1992
- The effects of deprenyl on methamphetamine-induced dopamine depletionsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1992
- SelegilineDrugs & Aging, 1991
- [3H]Ro 16–6491, a Selective Probe for Affinity Labelling of Monoamine Oxidase Type B in Human Brain and Platelet MembranesJournal of Neurochemistry, 1988
- Platelets as a model for neurones?Cellular and Molecular Life Sciences, 1988
- The pharmacology of Parkinson's disease: Basic aspects and recent advancesCellular and Molecular Life Sciences, 1984
- Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administrationJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1978
- The possible mechanisms of action of (-)deprenyl in Parkinson's diseaseJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1978